|Kim MJ, Shim DH, Cha HR, Moon KY, Yang CM, Hwang SJ, Kim KW, Park JH, Lee CG, Elias JA, Sohn MH, Lee JM. "Chitinase 3-like 1 protein plays a critical role in respiratory syncytial virus-induced airway inflammation." Allergy, 2018.|
|Shan Z, Liu X, Chen Y, Wang M, Gao YR, Xu L, Dar WA, Lee CG, Elias JA, Castillo PD, Di Paola J, Ju C. "Chitinase 3-like-1 promotes intrahepatic activation of coagulation through induction of tissue factor in mice." Hepatology, vol. 67, no. 6, 2018, pp. 2384-2396.|
|Hong, J. Y., Kim, M., Sol, I. S., Kim, K. W., Lee, C.-M., Elias, J. A., Sohn, M. H., Lee, C. G. "Chitotriosidase inhibits allergic asthmatic airways via regulation of TGF-β expression and Foxp3<sup>+</sup> Treg cells." Allergy, vol. 73, no. 8, 2018, pp. 1686-1699.|
|Lee CM, Cho SJ, Cho WK, Park JW, Lee JH, Choi AM, Rosas IO, Zheng M, Peltz G, Lee CG, Elias JA. "Laminin α1 is a genetic modifier of TGF-β1-stimulated pulmonary fibrosis." JCI Insight, vol. 3, no. 18, 2018.|
|Kim DH, Park HJ, Lim S, Koo JH, Lee HG, Choi JO, Oh JH, Ha SJ, Kang MJ, Lee CM, Lee CG, Elias JA, Choi JM. "Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis." Nature Communications, vol. 9, no. 1, 2018, pp. 503.|
|Murray LA, Habiel DM, Hohmann M, Camelo A, Shang H, Zhou Y, Coelho AL, Peng X, Gulati M, Crestani B, Sleeman MA, Mustelin T, Moore MW, Ryu C, Osafo-Addo AD, Elias JA, Lee CG, Hu B, Herazo-Maya JD, Knight DA, Hogaboam CM, Herzog EL. "Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis." JCI insight, vol. 2, no. 16, 2017.|
|Lee, Chang-Min, He, Chuan Hua, Nour, Adel M., Zhou, Yang, Ma, Bing, Park, Jin Wook, Kim, Kyung Hee, Cruz, Charles Dela, Sharma, Lokesh, Nasr, Mahmoud L., Modis, Yorgo, Lee, Chun Geun, Elias, Jack A. "IL-13Rα2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses." Nature Communications, vol. 7, 2016, pp. 12752.|
|Ma B, Herzog EL, Moore M, Lee CM, Na SH, Lee CG, Elias JA. "RIG-like Helicase Regulation of Chitinase 3-like 1 Axis and Pulmonary Metastasis." Scientific reports, vol. 6, 2016, pp. 26299.|
|Yoon PO, Park JW, Lee CM, Kim SH, Kim HN, Ko Y, Bae SJ, Yun S, Park JH, Kwon T, Kim WS, Lee J, Lu Q, Kang HR, Cho WK, Elias JA, Yang JS, Park HO, Lee K, Lee CG. "Self-assembled Micelle Interfering RNA for Effective and Safe Targeting of Dysregulated Genes in Pulmonary Fibrosis." Journal of Biological Chemistry, vol. 291, no. 12, 2016, pp. 6433-46.|
|Wiesner DL, Specht CA, Lee CK, Smith KD, Mukaremera L, Lee ST, Lee CG, Elias JA, Nielsen JN, Boulware DR, Bohjanen PR, Jenkins MK, Levitz SM, Nielsen K. "Chitin recognition via chitotriosidase promotes pathologic type-2 helper T cell responses to cryptococcal infection." PLoS pathogens, vol. 11, no. 3, 2015, pp. e1004701.|
|Ahangari, Farida, Sood, Akshay, Ma, Bing, Takyar, Seyedtaghi, Schuyler, Mark, Qualls, Clifford, Dela Cruz, Charles S., Chupp, Geoffrey L., Lee, Chun G., Elias, Jack A. "Chitinase 3–like-1 Regulates Both Visceral Fat Accumulation and Asthma-like Th2 Inflammation." Am J Respir Crit Care Med, vol. 191, no. 7, 2015, pp. 746-757.|
|Cho, Soo Jung, Weiden, Michael D., Lee, Chun Geun. "Chitotriosidase in the Pathogenesis of Inflammation, Interstitial Lung Diseases and COPD." Allergy, Asthma & Immunology Research, vol. 7, no. 1, 2015, pp. 14.|
|Vock, C., Yildirim, A. Ö., Wagner, C., Schlick, S., Lunding, L. P., Lee, C. G., Elias, J. A., Fehrenbach, H., Wegmann, M. "Distal airways are protected from goblet cell metaplasia by diminished expression of IL-13 signalling components." Clinical & Experimental Allergy, vol. 45, no. 9, 2015, pp. 1447-1458.|
|Patel AS, Song JW, Chu SG, Mizumura K, Osorio JC, Shi Y, El-Chemaly S, Lee CG, Rosas IO, Elias JA, Choi AM, Morse D. "Epithelial cell mitochondrial dysfunction and PINK1 are induced by transforming growth factor-beta1 in pulmonary fibrosis." PLoS ONE, vol. 10, no. 3, 2015, pp. e0121246.|
|Wang J, Liu W, Marion C, Singh R, Andrews N, Lee CG, Elias JA, Dela Cruz CS. "Interleukin-15 Regulates Retinoic Acid Receptor Beta in the Lung During Cigarette Smoking and Influenza Virus Infection." American Journal of Respiratory Cell and Molecular Biology, 2015.|
|Ma, B., Herzog, E. L., Lee, C. G., Peng, X., Lee, C.-M., Chen, X., Rockwell, S., Koo, J. S., Kluger, H., Herbst, R. S., Sznol, M., Elias, J. A. "Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis." Cancer Research, vol. 75, no. 3, 2015, pp. 487-496.|
|Kang MJ, Yoon CM, Nam M, Kim DH, Choi JM, Lee CG, Elias JA. "Role of Chitinase 3-like-1 in IL-18-induced Pulmonary Type-1, -2 and -17 Inflammation, Alveolar Destruction and Airway Fibrosis in the Murine Lung." American Journal of Respiratory Cell and Molecular Biology, 2015.|
|Kang MJ, Yoon CM, Kim BH, Lee CM, Zhou Y, Sauler M, Homer R, Dhamija A, Boffa D, West AP, Shadel GS, Ting JP, Tedrow JR, Kaminski N, Kim WJ, Lee CG, Oh YM, Elias JA. "Suppression of NLRX1 in chronic obstructive pulmonary disease." Journal of Clinical Investigation, vol. 125, no. 6, 2015, pp. 2458-62.|
|Sakhatskyy P, Gabino Miranda GA, Newton J, Lee CG, Choudhary G, Vang A, Rounds S, Lu Q. "Cigarette smoke-induced lung endothelial apoptosis and emphysema are associated with impairment of FAK and eIF2α." Microvascular Research, vol. 94, 2014, pp. 80-9.|
My role in basic and clinical research has largely derived from my position as Director of the Molecular Biology Core in the Section of Pulmonary Medicine. In that capacity, I have generated and characterized lung-specific overexpressing transgenic and null mutant mice to study in vivo roles and the effect of various cytokines in the pathogenesis of asthma, acute lung injury, pulmonary vascular disease, pulmonary fibrosis and emphysema.
KDDF-Bioneer-201312-11 (Lee/Chae) 2/11/2014- 10/10/2015
Korea Drug Development Fund (KDDF) $227,273
Selection of optimized lead compounds for preclinical studies for idiopathic pulmonary fibrosis using a novel RNAi-based nanoparticle technology SAMiRNA
Bioneer, a biotech company in Korea, developed Self Assembled Micelle-inhibitory RNA (SAMiRNA) technology as a novel and effective siRNA delivery method. In this project, the effectiveness of this SAMiRNA approach against pulmonary fibrosis will be determined through a variety of in vivo and in vitro evaluations and also using TGF-b transgenic mice developed by our laboratory as an animal model of pulmonary fibrosis. Thus, successful completion of this project will lead to the development of new drug for the effective intervention of pulmonary fibrosis.
Role: Principal Investigator
1 R01 HL115813-01A1 (Lee) 7/1/14 – 6/31/18
NIH / NHLBI $254,707
Chitinase 1 as a Biomarker and Therapeutic Target in Scleroderma Lung Disease
This grant proposes to define the roles and effects of chitinase1 in the pathogenesis of Scleroderma-associated interstitial lung disease. The studies in this project will evaluate the levels of chitinase1 in the blood or tissues of Scleroderma patients and controls to identify chitinase1 as a potential biomarker or a therapeutic target for this disease.
Role: Principal Investigator
1U01 HL 108638-01 (Elias) 8/15/11 – 6/30/15
NIH / NHLBI $396,455
YKL-40 in Idiopathic Pulmonary Fibrosis and Kidney Transplantation
This grant is designed to evaluate circulating YKL-40 as a biomarker for disease progression in IPF and urinary YKL-40 as a predictor of delayed graft function after renal transplantation. These studies will also evaluate the utility of YKL-40 as a therapeutic target in both disorders.
P01 HL114501-01A1 (Choi) 4/1/13 – 3/31/18
NIH / NHLBI $225,000
Distinct and Overlapping Pathways of Fibrosis and Emphysema in Cigarette Smokers
The focus is on the mechanisms that underlie the observation that cigarette smoke exposure and TGF-1 can contribute to the pathogenesis of COPD and IPF. Project 3 is based on evaluations of 10 different inbred murine backgrounds which define genetic modifiers that likely determine if TGF-1 causes fibrosis versus emphysema. These studies will define the expression of these modifiers in COPD and IPF and will define their roles in these biologic responses.
Role: Co-PI, Project 2
5 U01 HL108634 (Zhou/Elias) 9/1/13- 8/31/14 .
MAPGen Knowledge Base (MAPGenKB) and Coordination Center
In this ancillary project, we will measure the levels of YK-40 in patients with atherosclerosis, hypertension, metabolic syndromes and visceral fat accumulation. In addition, we will evaluate the roles of cell cycle regulation and the mitochondrial function in animal model of the diseases.
1 UH2 HL 123876-01 (Chupp/Elias) 7/1/14 – 6/30/19
Preclinical Development of a Novel Anti-YKL-40 Biologic to Treat Severe Asthma
We will complete the pre-clinical development of a humanized monoclonal antibody against the chitinase-like-protein, YKL-40, for the treatment of severe asthma. A companion diagnostic test will also be developed to measure YKL-40 in the serum that is drug-bound or free for monitoring the bioavailability, dosing, and biologic effect. The results will generate a novel therapeutic against a validated mediator of inflammation and remodeling in asthma and will lead to an Investigational New Drug (IND) application following the conclusion of the award.
NIH/ NHLBI 10/1/14 to 9/30/15
R56 HL 119511-01A1 (Bridge Award) (Kang)
NLRX1 and MAVS in cigarette smoke-induced inflammation and alveolar remodeling
The goal of this grant is to define the roles of novel mitochondrial molecules called NLRX1 and MAVS in the development of COPD. In addition, we will explore whether interventions that restore suppressed NLRX1 or modulate this pathway have therapeutic potential in a murine COPD model.
1981-1993 Full scholarship from Hanyang University for undergraduate and graduate courses, Hanyang
University, School of Medicine, Seoul Korea
1992-1993 Scholarship from Korean Public Health Institution, Seoul Korea
2005 Innovative Research Award, American Thoracic Society
1987 – 1992 Teaching Assistant, Hanyang University School of Medicine
1993 – 1995 Research Scientist, Division of Biotechnology, Korea National Institute of Health (KNIH)
1995 – 1996 Full-time Instructor, Hanyang University School of Medicine
1997 – 1998 Visiting fellow, LMM, NIAID, NIH
1998 – 1999 Post-doctoral fellow, Yale University School of Medicine
2000 – 2001 Associate Research Scientist, Yale University School of Medicine
2002 – 2007 Assistant Professor of Medicine, Yale University School of Medicine
2007 – 2009 Visiting Professor, Hanyang University School of Medicine
2002 - 2014 Director, Molecular Biology Core, Section of Pulmonary, Critical Care & Sleep Medicine, Yale University School of Medicine, New Haven, CT
2008 – 2014 Associate Professor of Medicine, Yale University School of Medicine
2014 – Present Professor, Dept of Molecular Microbiology and Immunology,
Division of Biology and Medical Sciences, Brown University